Compass Therapeutics to Present P-II Study Results of CTX-009 + Paclitaxel for Biliary Tract Cancers at ASCO GI 2023
Shots:
- The P-II study evaluating CTX-009 + paclitaxel in patients with BTC at 4 sites in Korea. Compass initiated a P-II/III trial of CTX-009 + paclitaxel in the US for BTC & BLA submission is expected in 2024
- At the data cut-off Nov 2022, 24 patients were enrolled & dosed with 1 cycle of CTX-009 & paclitaxel showed ORR (37.5%), 1 response was observed in each of the 4 anatomical subtypes of BTC, 9 with PR. In the sub-group analysis, 7 out of 11 patients achieved a PR who had received 1 prior systemic therapy with ORR (63.6%)
- After a median follow-up of ~12mos. m-OS (12.5mos.) & m-PFS (9.4mos.) supporting the durable effect of CTX-009, safety & tolerability remained consistent with prior studies, grade ≥3 TEAEs (95.8%)
Ref: Globenewswire | Image: Compass Therapeutics
Related News:- Elpiscience Partner Compass Report Interim Results of ES104 + Paclitaxel in P-II Study for the Treatment of Biliary Tract Cancers
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
